Knapp B, Wood C. The prehospital administration of intravenous methylprednisolone lowers hospital admission rates for moderate to severe asthma. Prehosp Emerg Care. 2003; 7:423–6.28 28 Gibbs MA, Camargo CA Jr., Rowe BH, Silverman RA. State of the art: therapeutic controversies in severe acute asthma. Acad Emerg Med. 2000; 7:800–15.
29 29 Nassif A, Ostermayer DG, Hoang KB, Claiborne MK, Camp EA, Shah MI. Implementation of a prehospital protocol change for asthmatic children. Prehosp Emerg Care. 2018; 22:457–65.
30 30 Conway J, Friedman B. Intravenous magnesium sulfate for acute asthma exacerbation in adults. Acad Emerg Med. Published online ahead of print June23, 2020. doi: 10.1111/acem.14066.
31 31 Kew KM, Kirtchuk L, Michell CI. Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department. Cochrane Database Syst Rev. 2014:CD010909.
32 32 Williams AM, Abramo TJ, Shah MV, et al. Safety and clinical findings of BiPAP utilization in children 20 kg or less for asthma exacerbations. Intensive Care Med. 2011; 3 7:1338–43.
33 33 Beers SL, Abramo TJ, Bracken A, Wiebe RA. Bilevel positive airway pressure in the treatment of status asthmaticus in pediatrics. Am J Emerg Med. 2007; 25:6–9.
34 34 Thapamagar SB, Doshi V, Shenoy S, Ganesh A, Lankala S. Outcomes of noninvasive ventilation in obese patients with acute asthma exacerbations. Am J Ther. 2018; 25:e635–41.
35 35 Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008; 31:1334–56.
36 36 Stoller JK, Aboussouan LS. Alpha1‐antitrypsin deficiency. Lancet 2005; 365:2225–36.
37 37 Heron M. Deaths: leading causes for 2017. Natl Vital Stat Rep. 2019; 68:1–77.
38 38 Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state‐specific medical and absenteeism costs of COPD among adults aged ≥18 years in the United States for 2010 and projections through 2020. Chest. 2015; 147:31–45.
39 39 Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990‐2010: burden of diseases, injuries, and risk factors. JAMA. 2013; 310:591–608.
40 40 Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: 2020 report. Available at: http://www.goldcopd.org. 2020. Accessed July 31, 2020.
41 41 Campbell IA, Colman SB, Mao JH, Prescott RJ, Weston CF. An open, prospective comparison of beta 2 agonists given via nebuliser, Nebuhaler, or pressurised inhaler by ambulance crew as emergency treatment. Thorax. 1995; 50:79–80.
42 42 Walters JA, Tan DJ, White CJ, Gibson PG, Wood‐Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev.. 2014:CD001288.
43 43 Ram FS, Rodriguez‐Roisin R, Granados‐Navarrete A, Garcia‐Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006:CD004403.
44 44 Osadnik CR, Tee VS, Carson‐Chahhoud KV, Picot J, Wedzicha JA, Smith BJ. Non‐invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017; 7:CD004104.
45 45 Celli BR. Update on the management of COPD. Chest. 2008; 133:1451–62.
46 46 Borlaug BA. Defining HFpEF: where do we draw the line? Eur Heart J 2016; 37:463–5.
47 47 Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics‐2017 update: a report from the American Heart Association. Circulation. 2017; 135:e146–e603.
48 48 McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left‐ventricular systolic dysfunction in an urban population. Lancet. 1997; 350:829–33.
49 49 Echouffo‐Tcheugui JB, Bishu KG, Fonarow GC, Egede LE. Trends in health care expenditure among US adults with heart failure: The Medical Expenditure Panel Survey 2002‐2011. Am Heart J. 2017; 186:63–72.
50 50 Neesse A, Jerrentrup A, Hoffmann S, et al. Prehospital chest emergency sonography trial in Germany: a prospective study. Eur J Emerg Med. 2012; 19:161–6.
51 51 Kallio T, Kuisma M, Alaspaa A, Rosenberg PH. The use of prehospital continuous positive airway pressure treatment in presumed acute severe pulmonary edema. Prehosp Emerg Care. 2003; 7:209–13.
52 52 Thompson J, Petrie DA, Ackroyd‐Stolarz S, Bardua DJ. Out‐of‐hospital continuous positive airway pressure ventilation versus usual care in acute respiratory failure: a randomized controlled trial. Ann Emerg Med. 2008; 52:232–41, e241.
53 53 Masip J, Roque M, Sanchez B, Fernandez R, Subirana M, Exposito JA. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta‐analysis. JAMA. 2005; 294:3124–30.
54 54 Naughton MT, Rahman MA, Hara K, Floras JS, Bradley TD. Effect of continuous positive airway pressure on intrathoracic and left ventricular transmural pressures in patients with congestive heart failure. Circulation. 1995; 91:1725–31.
55 55 Levy PD, Bellou A. Acute heart failure treatment. Curr Emerg Hosp Med Rep. 2013; 1112–21.
56 56 Engelberg S, Singer AJ, Moldashel J, Sciammarella J, Thode HC, Henry M. Effects of prehospital nitroglycerin on hemodynamics and chest pain intensity. Prehosp Emerg Care. 2000; 4:290–3.
57 57 Levy P, Compton S, Welch R, et al. Treatment of severe decompensated heart failure with high‐dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med. 2007; 50:144–52.
58 58 Wilson SS, Kwiatkowski GM, Millis SR, Purakal JD, Mahajan AP, Levy PD. Use of nitroglycerin by bolus prevents intensive care unit admission in patients with acute hypertensive heart failure. Am J Emerg Med. 2017; 35:126–31.
59 59 Patrick C, Ward B, Anderson J, et al. Feasibility, effectiveness and safety of prehospital intravenous bolus dose nitroglycerin in patients with acute pulmonary edema. Prehosp Emerg Care. 2020:1–7.
60 60 Wang K, Samai K. Role of high‐dose intravenous nitrates in hypertensive acute heart failure. Am J Emerg Med 2020; 38:132–7.
61 61 Hoffman JR, Reynolds S. Comparison of nitroglycerin, morphine and furosemide in treatment of presumed pre‐hospital pulmonary edema. Chest. 1987; 92:586–93.
62 62 Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G, Emerman CL. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med. 2008; 25:205–9.
63 63 Gray A, Goodacre S, Seah M, Tilley S. Diuretic, opiate and nitrate use in severe acidotic acute cardiogenic pulmonary oedema: analysis from the 3CPO trial. QJM. 2010; 103:573–81.
64 64 Kline JA, Courtney DM, Kabrhel C, et al. Prospective multicenter evaluation of the pulmonary embolism rule‐out criteria. J Thromb Haemos. 2008; 6:772–80.
65 65 Lee JA, Zierler BK, Zierler RE. The risk factors and clinical outcomes of upper extremity deep vein thrombosis. Vasc Endovascular Surg. 2012; 46:139–44.
66 66 Kosuge M, Kimura K, Ishikawa T, et al.
